{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T19:05:18Z","timestamp":1780340718131,"version":"3.54.1"},"reference-count":107,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ymgme.2024.108559","type":"journal-article","created":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T16:18:50Z","timestamp":1722701930000},"page":"108559","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Clinical insight meets scientific innovation to develop a next generation ERT for Pompe disease"],"prefix":"10.1016","volume":"143","author":[{"given":"Priya S.","family":"Kishnani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin-Hsiu","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth I.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nate","family":"Thibault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Sparks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ymgme.2024.108559_bb0005","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.ncl.2014.04.010","article-title":"Pompe disease: literature review and case series","volume":"32","author":"Dasouki","year":"2014","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.ymgme.2024.108559_bb0010","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1007\/s13311-018-0655-y","article-title":"Pompe disease: from basic science to therapy","volume":"15","author":"Kohler","year":"2018","journal-title":"Neurotherapeutics."},{"issue":"3","key":"10.1016\/j.ymgme.2024.108559_bb0015","first-page":"271","article-title":"Alglucosidase alfa: first available treatment for Pompe disease","volume":"4","author":"Nicolino","year":"2007","journal-title":"Clin. Pract."},{"issue":"6","key":"10.1016\/j.ymgme.2024.108559_bb0020","doi-asserted-by":"crossref","first-page":"e1116","DOI":"10.1542\/peds.2008-3667","article-title":"Pompe disease in infants: improving the prognosis by newborn screening and early treatment","volume":"124","author":"Chien","year":"2009","journal-title":"Pediatrics."},{"issue":"13","key":"10.1016\/j.ymgme.2024.108559_bb0025","doi-asserted-by":"crossref","first-page":"283","DOI":"10.21037\/atm.2019.04.70","article-title":"Long-term outcome and unmet needs in infantile-onset Pompe disease","volume":"7","author":"Hahn","year":"2019","journal-title":"Ann. Transl. Med."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108559_bb0030","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108559_bb0035","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/BF02265613","article-title":"The conduction system in Pompe\u2019s disease","volume":"2","author":"Bharati","year":"1982","journal-title":"Pediatr. Cardiol."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108559_bb0040","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3390\/ijns6020048","article-title":"Expanding newborn screening for Pompe disease in the United States: the NewSTEPs new disorders implementation project, a resource for new disorder implementation","volume":"6","author":"Hale","year":"2020","journal-title":"Int. J. Neonatal Screen."},{"issue":"4","key":"10.1016\/j.ymgme.2024.108559_bb0045","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ymgme.2011.04.009","article-title":"Expanding the clinical spectrum of late-onset Pompe disease: dilated arteriopathy involving the thoracic aorta, a novel vascular phenotype uncovered","volume":"103","author":"El-Gharbawy","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2024.108559_bb0050","series-title":"Toward Deconstructing the Phenotype of Late-Onset Pompe Disease","first-page":"80","author":"Sch\u00fcller","year":"2012"},{"issue":"5","key":"10.1016\/j.ymgme.2024.108559_bb0055","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.gim.0000218152.87434.f3","article-title":"Pompe disease diagnosis and management guideline","volume":"8","author":"Kishnani","year":"2006","journal-title":"Genet. Med."},{"issue":"9","key":"10.1016\/j.ymgme.2024.108559_bb0060","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1212\/01.WNL.0000142597.69707.78","article-title":"Late-onset Pompe disease primarily affects quality of life in physical health domains","volume":"63","author":"Hagemans","year":"2004","journal-title":"Neurology."},{"key":"10.1016\/j.ymgme.2024.108559_bb0065","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0304-4165(81)90474-8","article-title":"Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation","volume":"673","author":"Furbish","year":"1981","journal-title":"Biochim. Biophys. Acta (BBA)-Gen. Subj."},{"key":"10.1016\/j.ymgme.2024.108559_bb0070","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/BF00711365","article-title":"Modifying exogenous glucocerebrosidase for effective replacement therapy in Gaucher disease","volume":"17","author":"Brady","year":"1994","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2024.108559_bb0075","series-title":"Methods in Enzymology","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0076-6879(87)49041-1","article-title":"Lectin-specific targeting of lysosomal enzymes to reticuloendothelial cells","author":"Murray","year":"1987"},{"issue":"3","key":"10.1016\/j.ymgme.2024.108559_bb0080","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/j.1432-1033.1995.903_a.x","article-title":"Isolation and characterisation of a recombinant, precursor form of lysosomal acid \u03b1-glucosidase","volume":"234","author":"Fuller","year":"1995","journal-title":"Eur. J. Biochem."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108559_bb0085","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1073\/pnas.93.1.65","article-title":"High-level production of recombinant human lysosomal acid alpha-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease","volume":"93","author":"Van Hove","year":"1996","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"12","key":"10.1016\/j.ymgme.2024.108559_bb0090","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1093\/hmg\/8.12.2145","article-title":"Human acid \u03b1-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II","volume":"8","author":"Bijvoet","year":"1999","journal-title":"Hum. Mol. Genet."},{"issue":"4","key":"10.1016\/j.ymgme.2024.108559_bb0095","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.ymgme.2008.04.009","article-title":"Biochemical and pharmacological characterization of different recombinant acid \u03b1-glucosidase preparations evaluated for the treatment of Pompe disease","volume":"94","author":"McVie-Wylie","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2024.108559_bb0100","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1007\/BF02680006","article-title":"Enzyme therapy for Pompe disease: from science to industrial enterprise","volume":"161","author":"Reuser","year":"2002","journal-title":"Eur. J. Pediatr."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108559_bb0105","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid \u03b1-glucosidase: major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology."},{"issue":"5","key":"10.1016\/j.ymgme.2024.108559_bb0110","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease","volume":"148","author":"Kishnani","year":"2006","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2024.108559_bb0115","author":"Genzyme"},{"issue":"1","key":"10.1016\/j.ymgme.2024.108559_bb0120","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1042\/bj0860011","article-title":"alpha-Glucosidase deficiency in generalized glycogenstorage disease (Pompe\u2019s disease)","volume":"86","author":"Hers","year":"1963","journal-title":"Biochem. J."},{"issue":"21","key":"10.1016\/j.ymgme.2024.108559_bb0125","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","article-title":"Replacement therapy for inherited enzyme deficiency\u2014macrophage-targeted glucocerebrosidase for Gaucher\u2019s disease","volume":"324","author":"Barton","year":"1991","journal-title":"N. Engl. J. Med."},{"issue":"9227","key":"10.1016\/j.ymgme.2024.108559_bb0130","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(00)02533-2","article-title":"Recombinant human \u03b1-glucosidase from rabbit milk in Pompe patients","volume":"356","author":"Van den Hout","year":"2000","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ymgme.2024.108559_bb0135","first-page":"132","article-title":"Recombinant human acid \u03b1-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I\/II clinical trial","volume":"3","author":"Amalfitano","year":"2001","journal-title":"Genet. Med."},{"issue":"3","key":"10.1016\/j.ymgme.2024.108559_bb0140","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/GIM.0b013e31819d0996","article-title":"Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease","volume":"11","author":"Nicolino","year":"2009","journal-title":"Genet. Med."},{"issue":"15","key":"10.1016\/j.ymgme.2024.108559_bb0145","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","article-title":"A randomized study of alglucosidase alfa in late-onset Pompe\u2019s disease","volume":"362","author":"Van der Ploeg","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108559_bb0150","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jpeds.2006.02.035","article-title":"Chinese hamster ovary cell-derived recombinant human acid \u03b1-glucosidase in infantile-onset Pompe disease","volume":"149","author":"Kishnani","year":"2006","journal-title":"J. Pediatr."},{"issue":"3","key":"10.1016\/j.ymgme.2024.108559_bb0155","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1203\/PDR.0b013e3181b24e94","article-title":"Early treatment with alglucosidase alfa prolongs long-term survival of infants with Pompe disease","volume":"66","author":"Kishnani","year":"2009","journal-title":"Pediatr. Res."},{"issue":"4","key":"10.1016\/j.ymgme.2024.108559_bb0160","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/mus.21025","article-title":"Clinical features of late-onset Pompe disease: a prospective cohort study","volume":"38","author":"Wokke","year":"2008","journal-title":"Muscle & Nerve"},{"issue":"1","key":"10.1016\/j.ymgme.2024.108559_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1172-8-49","article-title":"Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study","volume":"8","author":"G\u00fcng\u00f6r","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2024.108559_bb0170","series-title":"Summary of Product Characteristics [Myozyme]. November 15, 2022","author":"Sanofi Genzyme","year":"2022"},{"issue":"1","key":"10.1016\/j.ymgme.2024.108559_bb0175","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1006\/abio.2000.4838","article-title":"Liquid chromatographic assay for a glucose tetrasaccharide, a putative biomarker for the diagnosis of Pompe disease","volume":"287","author":"An","year":"2000","journal-title":"Anal. Biochem."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108559_bb0180","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/clinchem\/48.1.131","article-title":"Determination of oligosaccharides in Pompe disease by electrospray ionization tandem mass spectrometry","volume":"48","author":"Rozaklis","year":"2002","journal-title":"Clin. Chem."},{"issue":"3","key":"10.1016\/j.ymgme.2024.108559_bb0185","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3390\/ijns6030055","article-title":"Establishing Pompe disease newborn screening: the role of industry","volume":"6","author":"Keutzer","year":"2020","journal-title":"Int. J. Neonatal Screen."},{"key":"10.1016\/j.ymgme.2024.108559_bb0190","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10545-006-0265-4","article-title":"Direct multiplex assay of enzymes in dried blood spots by tandem mass spectrometry for the newborn screening of lysosomal storage disorders","volume":"29","author":"Gelb","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"issue":"1\u20132","key":"10.1016\/j.ymgme.2024.108559_bb0195","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.cccn.2004.04.009","article-title":"Glycogen storage disease type II: enzymatic screening in dried blood spots on filter paper","volume":"347","author":"Chamoles","year":"2004","journal-title":"Clin. Chim. Acta"},{"issue":"4","key":"10.1016\/j.ymgme.2024.108559_bb0200","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.pedneo.2013.03.009","article-title":"Pompe disease: early diagnosis and early treatment make a difference","volume":"54","author":"Chien","year":"2013","journal-title":"Pediatr. Neonatol."},{"key":"10.1016\/j.ymgme.2024.108559_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2015.10.078","article-title":"Very early treatment for infantile-onset Pompe disease contributes to better outcomes","volume":"169","author":"Yang","year":"2016","journal-title":"J. Pediatr."},{"issue":"5","key":"10.1016\/j.ymgme.2024.108559_bb0210","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41436-020-01080-y","article-title":"Transforming the clinical outcome in CRIM-negative infantile Pompe disease identified via newborn screening: the benefits of early treatment with enzyme replacement therapy and immune tolerance induction","volume":"23","author":"Li","year":"2021","journal-title":"Genet. Med."},{"issue":"23","key":"10.1016\/j.ymgme.2024.108559_bb0215","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1056\/NEJMoa2200587","article-title":"In utero enzyme-replacement therapy for infantile-onset Pompe\u2019s disease","volume":"387","author":"Cohen","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"Supplement_1","key":"10.1016\/j.ymgme.2024.108559_bb0220","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1542\/peds.2016-0280E","article-title":"Management of confirmed newborn-screened patients with Pompe disease across the disease spectrum","volume":"140","author":"Kronn","year":"2017","journal-title":"Pediatrics."},{"issue":"139\u2013147","key":"10.1016\/j.ymgme.2024.108559_bb0225","article-title":"Outcome of later-onset Pompe disease identified through newborn screening","volume":"244","author":"Lee","year":"2022","journal-title":"J. Pediatr."},{"issue":"3","key":"10.1016\/j.ymgme.2024.108559_bb0230","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ymgme.2022.01.003","article-title":"Early clinical phenotype of late onset Pompe disease: lessons learned from newborn screening","volume":"135","author":"Huggins","year":"2022","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2024.108559_bb0235","article-title":"Advances in immune tolerance induction in enzyme replacement therapy","volume":"1-22","author":"\u0130nci","year":"2024","journal-title":"Pediatr. Drugs"},{"issue":"1","key":"10.1016\/j.ymgme.2024.108559_bb0240","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13052-022-01219-4","article-title":"Immune responses to alglucosidase in infantile Pompe disease: recommendations from an Italian pediatric expert panel","volume":"48","author":"Gragnaniello","year":"2022","journal-title":"Ital. J. Pediatr."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108559_bb0245","doi-asserted-by":"crossref","first-page":"36182","DOI":"10.1038\/srep36182","article-title":"Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients","volume":"6","author":"Masat","year":"2016","journal-title":"Sci. Rep."},{"issue":"13","key":"10.1016\/j.ymgme.2024.108559_bb0250","doi-asserted-by":"crossref","first-page":"285","DOI":"10.21037\/atm.2019.05.27","article-title":"Immunological challenges and approaches to immunomodulation in Pompe disease: a literature review","volume":"7","author":"Desai","year":"2019","journal-title":"Ann. Transl. Med."},{"issue":"8","key":"10.1016\/j.ymgme.2024.108559_bb0255","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","article-title":"The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease","volume":"13","author":"Banugaria","year":"2011","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2024.108559_bb0260","author":"Genzyme Corporation"},{"issue":"614856","key":"10.1016\/j.ymgme.2024.108559_bb0265","first-page":"1","article-title":"Immunogenicity of proteins used as therapeutics","volume":"11","author":"Sauna","year":"2020","journal-title":"Front. Media SA."},{"key":"10.1016\/j.ymgme.2024.108559_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.bej.2020.107750","article-title":"Glycosylation of Erwinase results in active protein less recognized by antibodies","volume":"163","author":"Effer","year":"2020","journal-title":"Biochem. Eng. J."},{"key":"10.1016\/j.ymgme.2024.108559_bb0275","article-title":"Earlier and higher dosing of alglucosidase alfa improve outcomes in patients with infantile-onset Pompe disease: evidence from real-world experiences","volume":"23","author":"Chien","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"5","key":"10.1016\/j.ymgme.2024.108559_bb0280","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/s41436-019-0738-0","article-title":"Higher dosing of alglucosidase alfa improves outcomes in children with Pompe disease: a clinical study and review of the literature","volume":"22","author":"Khan","year":"2020","journal-title":"Genet. Med."},{"issue":"6","key":"10.1016\/j.ymgme.2024.108559_bb0285","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/jimd.12268","article-title":"Effects of higher and more frequent dosing of alglucosidase alfa and immunomodulation on long-term clinical outcome of classic infantile Pompe patients","volume":"43","author":"Poelman","year":"2020","journal-title":"J. Inherit. Metab. Dis."},{"issue":"4","key":"10.1016\/j.ymgme.2024.108559_bb0290","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.nmd.2014.12.004","article-title":"Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease","volume":"25","author":"Case","year":"2015","journal-title":"Neuromuscul. Disord."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108559_bb0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-023-02981-2","article-title":"Higher dose alglucosidase alfa is associated with improved overall survival in infantile-onset Pompe disease (IOPD): data from the Pompe registry","volume":"18","author":"Kishnani","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2024.108559_bb0300","first-page":"67","article-title":"Baseline urinary glucose Tetrasaccharide concentrations in patients with infantile- and late-onset Pompe disease identified by newborn screening","volume":"19","author":"Chien","year":"2015","journal-title":"JIMD Rep."},{"issue":"4","key":"10.1016\/j.ymgme.2024.108559_bb0305","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ymgme.2005.03.010","article-title":"Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease","volume":"85","author":"An","year":"2005","journal-title":"Mol. Genet. Metab."},{"issue":"13","key":"10.1016\/j.ymgme.2024.108559_bb0310","doi-asserted-by":"crossref","DOI":"10.21037\/atm.2019.05.56","article-title":"Pompe disease gene therapy: neural manifestations require consideration of CNS directed therapy","volume":"7","author":"Byrne","year":"2019","journal-title":"Ann. Transl. Med."},{"issue":"6","key":"10.1016\/j.ymgme.2024.108559_bb0315","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/dmcn.13740","article-title":"Classic infantile Pompe patients approaching adulthood: a cohort study on consequences for the brain","volume":"60","author":"Ebbink","year":"2018","journal-title":"Dev. Med. Child Neurol."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108559_bb0320","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ymgme.2017.04.014","article-title":"Cognitive and academic outcomes in long-term survivors of infantile-onset Pompe disease: a longitudinal follow-up","volume":"121","author":"Spiridigliozzi","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2024.108559_bb0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-020-01482-w","article-title":"Distal muscle weakness is a common and early feature in long-term enzyme-treated classic infantile Pompe patients","volume":"15","author":"van den Dorpel","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2024.108559_bb0330","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.gim.2022.10.005","article-title":"Evaluating brain white matter hyperintensity, IQ scores, and plasma neurofilament light chain concentration in early-treated patients with infantile-onset Pompe disease","volume":"25","author":"Hsu","year":"2023","journal-title":"Genet. Med."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108559_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.108119","article-title":"Severe CNS involvement in a subset of long-term treated children with infantile-onset Pompe disease","volume":"141","author":"Kenney-Jung","year":"2024","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2024.108559_bb0340","first-page":"1","article-title":"Long-term outcome of infantile onset pompe disease patients treated with enzyme replacement therapy-data from a German-Austrian Cohort","author":"Pfrimmer","year":"2024","journal-title":"J. Neuromusc. Dis."},{"issue":"4","key":"10.1016\/j.ymgme.2024.108559_bb0345","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/jimd.12736","article-title":"Long term survival in patients with classic infantile Pompe disease reveals a spectrum with progressive brain abnormalities and changes in cognitive functioning","volume":"47","author":"van den Dorpel","year":"2024","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2024.108559_bb0350","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s10545-011-9404-7","article-title":"Facial-muscle weakness, speech disorders and dysphagia are common in patients with classic infantile Pompe disease treated with enzyme therapy","volume":"35","author":"van Gelder","year":"2012","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2024.108559_bb0355","first-page":"59","article-title":"Lower urinary tract symptoms and incontinence in children with Pompe disease","volume":"28","author":"Ajay","year":"2016","journal-title":"JIMD Rep."},{"issue":"6","key":"10.1016\/j.ymgme.2024.108559_bb0360","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3928\/01913913-20140813-01","article-title":"Ocular and histologic findings in a series of children with infantile pompe disease treated with enzyme replacement therapy","volume":"51","author":"Prakalapakorn","year":"2014","journal-title":"J. Pediatr. Ophthalmol. Strabismus"},{"issue":"4","key":"10.1016\/j.ymgme.2024.108559_bb0365","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.jpeds.2014.10.068","article-title":"Long-term prognosis of patients with infantile-onset Pompe disease diagnosed by newborn screening and treated since birth","volume":"166","author":"Chien","year":"2015","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2024.108559_bb0370","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1007\/s00415-021-10409-9","article-title":"STIG study: real-world data of long-term outcomes of adults with Pompe disease under enzyme replacement therapy with alglucosidase alfa","volume":"268","author":"Gutschmidt","year":"2021","journal-title":"J. Neurol."},{"issue":"19","key":"10.1016\/j.ymgme.2024.108559_bb0375","doi-asserted-by":"crossref","first-page":"e1756","DOI":"10.1212\/WNL.0000000000008441","article-title":"Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease","volume":"93","author":"Harlaar","year":"2019","journal-title":"Neurology."},{"issue":"23","key":"10.1016\/j.ymgme.2024.108559_bb0380","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1212\/WNL.0000000000004711","article-title":"Long-term benefit of enzyme replacement therapy in Pompe disease: a 5-year prospective study","volume":"89","author":"Kuperus","year":"2017","journal-title":"Neurology."},{"key":"10.1016\/j.ymgme.2024.108559_bb0385","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00415-016-8219-8","article-title":"Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis","volume":"264","author":"Schoser","year":"2017","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.ymgme.2024.108559_bb0390","first-page":"605","article-title":"Sorting of lysosomal proteins. Biochimica et Biophysica Acta (BBA)-molecular","volume":"1793","author":"Braulke","year":"2009","journal-title":"Cell Res."},{"issue":"3","key":"10.1016\/j.ymgme.2024.108559_bb0395","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0021-9258(18)53985-5","article-title":"Structural and functional changes of lysosomal acid alpha-glucosidase during intracellular transport and maturation","volume":"268","author":"Wisselaar","year":"1993","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.ymgme.2024.108559_bb0400","doi-asserted-by":"crossref","first-page":"6780","DOI":"10.1074\/jbc.M404008200","article-title":"Lysosomal acid \u03b1-glucosidase consists of four different peptides processed from a single chain precursor","volume":"280","author":"Moreland","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2024.108559_bb0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100769","article-title":"Endolysosomal N-glycan processing is critical to attain the most active form of the enzyme acid alpha-glucosidase","volume":"296","author":"Selvan","year":"2021","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108559_bb0410","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ymgme.2011.02.006","article-title":"Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle","volume":"103","author":"Koeberl","year":"2011","journal-title":"Mol. Genet. Metab."},{"issue":"4","key":"10.1016\/j.ymgme.2024.108559_bb0415","first-page":"723","article-title":"Quantitation of Mr 46000 and Mr 300000 mannose 6-phosphate receptors in human cells and tissues","volume":"23","author":"Wenk","year":"1991","journal-title":"Biochem. Int."},{"key":"10.1016\/j.ymgme.2024.108559_bb0420","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s10545-011-9285-9","article-title":"Biotherapeutic target or sink: analysis of the macrophage mannose receptor tissue distribution in murine models of lysosomal storage diseases","volume":"34","author":"Zhang","year":"2011","journal-title":"J. Inherit. Metab. Dis."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108559_bb0425","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ymgme.2015.09.012","article-title":"A beta-blocker, propranolol, decreases the efficacy from enzyme replacement therapy in Pompe disease","volume":"117","author":"Han","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2024.108559_bb0430","first-page":"31","article-title":"Albuterol as an adjunctive treatment to enzyme replacement therapy in infantile-onset Pompe disease","volume":"11","author":"Chien","year":"2017","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"5","key":"10.1016\/j.ymgme.2024.108559_bb0435","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1096\/fj.13-241893","article-title":"Adjunctive albuterol enhances the response to enzyme replacement therapy in late-onset Pompe disease","volume":"28","author":"Koeberl","year":"2014","journal-title":"FASEB J."},{"key":"10.1016\/j.ymgme.2024.108559_bb0440","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.omtm.2022.09.010","article-title":"IGF2-tagging of GAA promotes full correction of murine Pompe disease at a clinically relevant dosage of lentiviral gene therapy","volume":"27","author":"Liang","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"14","key":"10.1016\/j.ymgme.2024.108559_bb0445","doi-asserted-by":"crossref","first-page":"7962","DOI":"10.1016\/S0021-9258(18)83136-2","article-title":"Ligand interactions of the cation-independent mannose 6-phosphate receptor: the stoichiometry of mannose 6-phosphate binding","volume":"264","author":"Tong","year":"1989","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.ymgme.2024.108559_bb0450","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1016\/j.bbrc.2017.12.101","article-title":"Four unreported types of glycans containing mannose-6-phosphate are heterogeneously attached at three sites (including newly found Asn 233) to recombinant human acid alpha-glucosidase that is the only approved treatment for Pompe disease","volume":"495","author":"Park","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"48","key":"10.1016\/j.ymgme.2024.108559_bb0455","doi-asserted-by":"crossref","first-page":"50336","DOI":"10.1074\/jbc.M409676200","article-title":"Conjugation of mannose 6-phosphate-containing oligosaccharides to acid \u03b1-glucosidase improves the clearance of glycogen in Pompe mice","volume":"279","author":"Zhu","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.ymgme.2024.108559_bb0460","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/mt.2009.37","article-title":"Glycoengineered acid \u03b1-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease","volume":"17","author":"Zhu","year":"2009","journal-title":"Mol. Ther."},{"issue":"12","key":"10.1016\/j.ymgme.2024.108559_bb0465","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1021\/bc400365a","article-title":"Glycan structure determinants for cation-independent mannose 6-phosphate receptor binding and cellular uptake of a recombinant protein","volume":"24","author":"Zhou","year":"2013","journal-title":"Bioconjug. Chem."},{"issue":"4","key":"10.1016\/j.ymgme.2024.108559_bb0470","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1021\/bc1005416","article-title":"Strategies for neoglycan conjugation to human acid \u03b1-glucosidase","volume":"22","author":"Zhou","year":"2011","journal-title":"Bioconjug. Chem."},{"issue":"12","key":"10.1016\/j.ymgme.2024.108559_bb0475","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S1474-4422(21)00241-6","article-title":"Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial","volume":"20","author":"Diaz-Manera","year":"2021","journal-title":"Lancet Neurol."},{"issue":"13","key":"10.1016\/j.ymgme.2024.108559_bb0480","doi-asserted-by":"crossref","DOI":"10.21037\/atm.2019.04.15","article-title":"Challenges in treating Pompe disease: an industry perspective","volume":"7","author":"Do","year":"2019","journal-title":"Ann. Transl. Med."},{"issue":"7","key":"10.1016\/j.ymgme.2024.108559_bb0485","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040776","article-title":"The pharmacological chaperone AT2220 increases recombinant human acid \u03b1-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease","volume":"7","author":"Khanna","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.ymgme.2024.108559_bb0490","doi-asserted-by":"crossref","first-page":"e536","DOI":"10.1212\/WNL.0000000000200746","article-title":"Long-term safety and efficacy of avalglucosidase alfa in patients with late-onset pompe disease","volume":"99","author":"Dimachkie","year":"2022","journal-title":"Neurology."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108559_bb0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2022.10.010","article-title":"Safety and efficacy of avalglucosidase alfa in individuals with infantile-onset Pompe disease enrolled in the phase 2, open-label Mini-COMET study: the 6-month primary analysis report","volume":"25","author":"Kishnani","year":"2023","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2024.108559_bb0500","doi-asserted-by":"crossref","first-page":"1309146","DOI":"10.3389\/fgene.2024.1309146","article-title":"Real-world outcomes from a series of patients with late onset Pompe disease who switched from alglucosidase alfa to avalglucosidase alfa","volume":"15","author":"Carter","year":"2024","journal-title":"Front. Genet."},{"issue":"12","key":"10.1016\/j.ymgme.2024.108559_bb0505","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S1474-4422(21)00331-8","article-title":"Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial","volume":"20","author":"Schoser","year":"2021","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.ymgme.2024.108559_bb0510","doi-asserted-by":"crossref","DOI":"10.1212\/CPJ.0000000000200181","article-title":"Measurement properties of 2 novel PROs, the Pompe disease symptom scale and Pompe disease impact scale, in the COMET study","volume":"13","author":"Dimachkie","year":"2023","journal-title":"Neurol. Clin. Pract."},{"issue":"2","key":"10.1016\/j.ymgme.2024.108559_bb0515","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.108121","article-title":"Effect of avalglucosidase alfa on disease-specific and general patient-reported outcomes in treatment-na\u00efve adults with late-onset Pompe disease compared with alglucosidase alfa: Meaningful change analyses from the Phase 3 COMET trial","volume":"141","author":"Toscano","year":"2024","journal-title":"Mol. Genet. Metab."},{"issue":"3","key":"10.1016\/j.ymgme.2024.108559_bb0520","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20211057","article-title":"Molecular architecture determines brain delivery of a transferrin receptor\u2013targeted lysosomal enzyme","volume":"219","author":"Arguello","year":"2022","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymgme.2024.108559_bb0525","first-page":"3","article-title":"Antisense oligonucleotide-mediated suppression of muscle glycogen synthase 1 synthesis as an approach for substrate reduction therapy of Pompe disease","author":"Clayton","year":"2014","journal-title":"Mol. Ther.\u2013Nucleic Acids"},{"issue":"1","key":"10.1016\/j.ymgme.2024.108559_bb0530","doi-asserted-by":"crossref","first-page":"6393","DOI":"10.1038\/s41467-021-26744-4","article-title":"Hepatic expression of GAA results in enhanced enzyme bioavailability in mice and non-human primates","volume":"12","author":"Costa-Verdera","year":"2021","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.ymgme.2024.108559_bb0535","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1042\/BJ20050364","article-title":"Carbohydrate-remodelled acid \u03b1-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice","volume":"389","author":"Zhu","year":"2005","journal-title":"Biochem. J."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719224004438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719224004438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T02:20:49Z","timestamp":1742437249000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719224004438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":107,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1096719224004438"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2024.108559","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical insight meets scientific innovation to develop a next generation ERT for Pompe disease","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2024.108559","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108559"}}